Cannabidiol Therapeutics Company Secured FDA ODD For Pericarditis Treatment

Cardiol Therapeutics Secures FDA Orphan Drug Designation for Cannabidiol in the Treatment of Pericarditis.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In an unprecedented move, Cardiol Therapeutics Inc., a leader in the production of pharmaceutical cannabidiol (CBD), has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (…